RNA干扰技术应用于急性早幼粒细胞白血病治疗的实验研究进展  

Experimental Research Progress of RNA Interference Technology in Treatment of Acute Promyelocytic Leukemia

作　　者：宫文洁 徐建民[1] 

机构地区：[1]复旦大学中山医院血液科,上海200032

出　　处：《国际输血及血液学杂志》2014年第6期542-546,共5页International Journal of Blood Transfusion and Hematology

基　　金：上海癌症研究中心2010年资助项目

摘　　要：急性早幼粒细胞白血病（APL）是常见的血液系统肿瘤.几乎所有APL患者均伴有特异性的染色体t（15;17）（q22;q21）易位,并形成特征性的早幼粒细胞白血病/维甲酸受体α（PML/RARα）融合基因.RNA干扰（RNAi）技术具有转录后基因沉默效应,可特异性地抑制癌基因、癌相关基因或突变基因的过度表达,因此在疾病的基因治疗方面得到广泛关注.目前,RNAi技术治疗APL可选择的靶点主要有①PML/RARα融合基因;②APL细胞与正常细胞之间的差异基因;③涉及APL髓外复发、出血及其并发症的基因.现就近年来RNAi技术应用于APL治疗的实验研究进展作一综述.Acute promyelocytic leukemia （APL） is a common cancer of the blood system.Almost all APL patients are characterized by the presence of a chromosomal translocation in t （15 ; 17） （q22 ; q21）,that results in the generation of characteristic oncogenic fusion promyelocytic leukemia-retinoic acid receptor α （PML/RARα）.RNA interference （RNAi） technology is a post-transcriptional gene silencing technology,which can specifically inhibit the overexpression of oncogenes,cancer-related genes and mutation genes.Thus a widespread attention is focused on RNAi technology in terms of gene therapy.Currently,mainly selectable targets of RNAi technology in treatment of APL include three aspects：① PML/RARα fusion gene; ② genes differing in APL cells and normal cells; ③ genes involving extramedullary relapse,bleeding and other complications.In this article,we reviewed the experimental research progress of RNAi technology in treatment of APL.

关 键 词：RNA干扰 白血病 早幼粒细胞 急性 基因沉默 

分 类 号：R733.71[医药卫生—肿瘤]